A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

NCT ID: NCT00502138

Last Updated: 2013-01-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-07-31
• Study Completion Date: 2008-01-31

Brief Summary

This research project will investigate the effects of pramlintide (Symlin) given by continuous subcutaneous (under the skin) infusion throughout the day and night, along with meal doses similar to those injected during conventional pramlintide (Symlin) treatment, delivered using a second insulin pump, in subjects with inadequately controlled type I diabetes mellitus who are already using insulin pump therapy. Study participants will wear two pumps for a four month period, taking insulin in their usual manner and pramlintide (Symlin) in a similar basal/bolus fashion. Continuous glucose monitors will be worn on three occasions during the study to assess blood glucose responses to continuous pramlintide (Symlin) treatment.

Detailed Description

DESCRIPTION OF STUDY:

To participate in the study, you must have Type I diabetes mellitus and be taking insulin using an insulin pump, and have a hemoglobin A1c level between 7.0% and 10.0%. You will not be permitted to participate in the study if you have taken pramlintide (Symlin) during the previous three months. The study will consist of seven visits to the Study Center over a four-month period. Subjects will undergo meal tolerance testing at beginning and end of study period. Continuous blood glucose monitoring will be performed on three occasions during the study.

Pramlintide will be begun at a single basal rate of 1.5 units/hr. Bolus therapy will be begun thereafter per standard manufacturer protocol. Subjects will be monitored for three months on basal-bolus pramlintide therapy.

Conditions

IDDM

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

A

Interventional, continuous pramlintide infusion at 9 micrograms/hr plus 60 microgram meal bolus plus continuous insulin basal-bolus subcutaneous infusion

Group Type: EXPERIMENTAL

Continuous Pramlintide infusion

Intervention Type: DRUG

pramlintide injection, 9 mcg/hr plus 60 mcg premeal boluses

Interventions

Continuous Pramlintide infusion

pramlintide injection, 9 mcg/hr plus 60 mcg premeal boluses

Intervention Type: DRUG

Other Intervention Names

pramlintide

Eligibility Criteria

Inclusion Criteria

1. Type 1 diabetes of at least one year duration;

2. Treated with CSII therapy for at least 6 months;

3. Age 18 to 70 years, inclusive;

4. A1C >7.0 and ≤10% as screening;

5. BMI ≤35 kg/m2;

6. Stable insulin dose (±10%) for at least 3 months prior to screening;

7. If female, has a negative urine pregnancy test at screening;

8. If female and of childbearing potential, practicing and willing to continue to using appropriate contraception to ensure that pregnancy does not occur during the study;

9. Able to understand and sign the required study documents and comply with the protocol requirements

Exclusion Criteria

1. Is poorly compliant with the currently prescribed insulin regimen, as determined by the investigator;

2. Has any significant medical condition, laboratory findings, or medical history that may affect successful completion of the study and/or personal well-being;

3. If female and if of childbearing potential, is pregnant, lactating, or planning to become pregnant;

4. Has experienced recurrent severe hypoglycemia requiring assistance during the past 6 months;

5. Has a history of hypoglycemia unawareness;

6. Has a confirmed diagnosis of gastroparesis;

7. Requires the use of drugs that stimulate gastrointestinal motility;

8. Is receiving medications known to interfere with glycemic control (i.e. glucocorticoids);

9. Has been treated with any oral antidiabetic agent or exenatide within 3 months of screening visit;

10. Has been treated with pramlintide within 3 months of screening visit;

11. Has received an investigational drug within 3 month of screening visit;

12. Is currently participating in a clinical trial

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Amylin Pharmaceuticals, LLC.

INDUSTRY

Sponsor Role: collaborator

University Diabetes & Endocrine Consultants

OTHER

Sponsor Role: lead

Responsible Party

David M. Huffman MD

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

David M Huffman, MD

Role: PRINCIPAL_INVESTIGATOR

University Diabetes & Endocrine Consultants

Locations

University Diabetes & Endocrine Consultants

Chattanooga, Tennessee, United States

Countries

United States

References

Huffman DM, McLean GW, Seagrove MA. Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study. Endocr Pract. 2009 Nov-Dec;15(7):689-95. doi: 10.4158/EP09044.ORR1.

Reference Type: DERIVED

PMID: 19546056 (View on PubMed)

Other Identifiers

Pramlintide Infusion in IDDM

Identifier Type: -

Identifier Source: org_study_id